



truscreen
a world without
cervical cancer

NZX/ASX Announcement

26 February 2026

FY2026 Results Guidance

Truscreen Group Limited (NZX/ASX: TRU) (**TruScreen** or the Company), a global provider of AI-enabled products, today provides updated revenue and earnings guidance for the financial year ending 31 March 2026 (FY2026).¹

FY2026 revenue guidance¹

- FY2026 product sales revenue is expected to be approximately NZ\$2.4 million, representing an increase of 41% on FY2025, but below the market guidance of NZ\$2.8 million¹.
- The variance is primarily due to;
 - While a signed sales contract was received from Uzbekistan, the Company is still waiting for payment to be received prior to shipment.
 - a delay in the validation programme in Zimbabwe, which has deferred the anticipated second order of 10,000 SUS units into FY2027.
- Total revenue for FY2026 is expected to be approximately NZ\$2.7 million, an increase of around 28% on FY2025.

FY2026 Earnings guidance

- The Group expects to report a result similar to FY2025 a loss of ~NZ\$2.2 million, reflecting additional market access development costs. The Australian Research & Development tax refund offset is expected to be NZ\$200,000 lower than FY2025 from reduced R&D expenditure.¹
- During FY2026, TruScreen has invested in expanding its distributor network and market presence in Uzbekistan, India, Indonesia and selected African markets. These investments are intended to build the critical mass of product adoption and market access required to support the Company's path to sustainable profitability over the medium term. The recent publication of the 15,000 patients over 4 years clinical study by COGA (Chinese Obstetricians and Gynaecologists Association) has provided positive interest in our AI enable TruScreen technology.¹

The Board considers that providing updated quantitative guidance, together with the key underlying assumptions and drivers, is important to ensure the market is kept informed in accordance with the Company's continuous disclosure obligations.¹

This announcement has been approved for release by the Board of TruScreen Group Limited.

Ends

For more information, visit www.truscreen.com or contact:

Tony Ho
Executive Chairman
tonyho@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

¹ Investor presentation 11 September 2025

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra[®], is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer".

To learn more, please visit: www.truscreen.com/.

**Based on Single Use Sensor sales.*